SCHEMBL254704

SCHEMBL254704

C[C@@H]1CCCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31121560 1.00
SCHEMBL9926301 1.00
SCHEMBL37613 1.00
SCHEMBL28458927 0.97
SCHEMBL8223766 0.97
SCHEMBL23648162 0.97
SCHEMBL28199160 0.97
SCHEMBL250240 0.97
SCHEMBL3346847 0.97
Ammonia Solution, Strong SCHEMBL4765003 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270209-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. 2025-08-28 US disclosed
US-12398136-B2 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors VENTUS THERAPEUTICS U.S., INC. (US) 2025-08-26 US disclosed
US-12331048-B2 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors VENTUS THERAPEUTICS U.S., INC. (US) 2025-06-17 US disclosed
US-20240409540-A1 PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS VENTUS THERAPEUTICS U S INC (US) 2024-12-12 US disclosed
US-20240383896-A1 PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS VENTUS THERAPEUTICS U.S., INC. 2024-11-21 US disclosed
US-20240360130-A1 PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS VENTUS THERAPEUTICS U.S., INC. 2024-10-31 US disclosed
WO-2024148091-A1 CDK2 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2024-07-11 WO disclosed
WO-2024148087-A1 CDK2 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2024-07-11 WO disclosed
US-20240174661-A1 PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORS VENTUS THERAPEUTICS U.S., INC. 2024-05-30 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-20090281099-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE ANDRES-GIL JOSE IGNACIO 2009-11-12 US disclosed
US-20090281099-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE ANDRES-GIL JOSE IGNACIO 2009-11-12 US disclosed
US-20090111801-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US disclosed
US-20090111801-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-30 US disclosed
EP-1972641-A2 Resist composition and pattern-forming method using same FUJIFILM Corporation (JP) 2008-09-24 EP disclosed
WO-2007135131-A9 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA NV (BE) 2008-04-03 WO disclosed
EP-1592700-B1 AVERMECTIN- AND AVERMECTIN MONOSACCHARIDE DERIVATIVES SUBSTITUTED IN THE 4''- OR 4'- POSITION HAVING PESTICIDAL PROPERTIES MERIAL LTD (GB) 2008-04-02 EP disclosed
WO-2007135131-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 WO disclosed
WO-2007122173-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
WO-2007025089-A2 TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICAL, INC. (US) 2007-03-01 WO disclosed